{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:56:47Z","timestamp":1787021807063,"version":"build-2736575974"},"reference-count":79,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:00:00Z","timestamp":1609200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter-2 (SGLT2) inhibitors (SGLT2i) showed benefits in type 1 diabetes mellitus (T1DM), but the risk of diabetic ketoacidosis (DKA) limits their use. Ability to predict DKA risk and therapeutic responses would enable appropriate patient selection for SGLT2i. We conducted a meta-analysis and meta-regression of randomized controlled trials (RCTs) evaluating SGLT2i in T1DM to assess moderators of the relative risk (RR) of DKA, of glycemic (HbA1c, fasting plasma glucose, continuous glucose monitoring parameters, insulin dose, and insulin sensitivity indices) and non-glycemic (body mass index (BMI), systolic BP, renal function, albuminuria, and diabetic eye disorders) efficacy, and of other safety outcomes (including hypoglycemia, infections, major adverse cardiovascular events, and death).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We searched MEDLINE, Cochrane Library, EMBASE,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/\" xlink:type=\"simple\">ClinicalTrials.gov<\/jats:ext-link>\n                      , Cochrane CENTRAL Register of Controlled Trials, and other electronic sources through August 30, 2020, for RCTs comparing SGLT2i with active comparators or placebo in adult patients with T1DM. Reviewers extracted data for relevant outcomes, performed random effects meta-analyses, subgroup analyses, and multivariable meta-regression. The strength of evidence was summarized with the GRADE approach. Among 9,914 records identified, 18 placebo-controlled RCTs (7,396 participants, 50% males, mean age 42 y (range 23 to 55 y), 5 different SGLT2i evaluated), were included. Main outcome measures were effect sizes and moderators of glycemic and non-glycemic efficacy and of safety outcomes. In a multivariable meta-regression model, baseline BMI (\u03b2 = 0.439 [95% CI: 0.211, 0.666],\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) and estimated glucose disposal rate (eGDR) (\u03b2 = \u22120.766 [\u22121.276, \u22120.256],\n                      <jats:italic>p<\/jats:italic>\n                      = 0.001) were associated with the RR of DKA (RR: 2.81; 95% CI:1.97, 4.01;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001, R\n                      <jats:sup>2<\/jats:sup>\n                      = 61%). A model including also treatment-related parameters (insulin dose change-to-baseline insulin sensitivity ratio and volume depletion) explained 86% of variance across studies in the risk of DKA (R\n                      <jats:sup>2<\/jats:sup>\n                      = 86%). The association of DKA with a BMI &gt;27 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and with an eGDR &lt;8.3 mg\/kg\/min was confirmed also in subgroup analyses. Among efficacy outcomes, the novel findings were a reduction in albuminuria (WMD: \u22129.91, 95% CI: \u221216.26, \u22123.55 mg\/g,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002), and in RR of diabetic eye disorders (RR: 0.27[0.11, 0.67],\n                      <jats:italic>p<\/jats:italic>\n                      = 0.005) associated with SGLT2i. A SGLT2i dose-response gradient was consistently observed for main efficacy outcomes, but not for adverse events (AEs). Overall, predictors of DKA and of other AEs differed substantially from those of glycemic and non-glycemic efficacy. A limitation of our analysis was the relatively short (\u226452 weeks) duration of included RCTs. The potential relevance for clinical practice needs also to be confirmed by real-world prospective studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In T1DM, the risk of DKA and main therapeutic responses to SGLT2i are modified by baseline BMI and insulin resistance, by total insulin dose reduction-to-baseline insulin sensitivity ratio, and by volume depletion, which may enable the targeted use of these drugs in patients with the greatest benefit and the lowest risk of DKA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1003461","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T13:24:50Z","timestamp":1609248290000},"page":"e1003461","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":58,"title":["Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8569-2872","authenticated-orcid":true,"given":"Giovanni","family":"Musso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Sircana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cassader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gambino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,12,29]]},"reference":[{"key":"pmed.1003461.ref001","unstructured":"US Center for Disease Control and Prevention; http:\/\/www.cdc.gov\/diabetes\/pubs\/statsreport14\/diabetesinfographic.pdf; accessed November 30th 2018."},{"key":"pmed.1003461.ref002","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00125-018-4763-3","article-title":"Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989\u20132013: a multicentre prospective registration study","volume":"62","author":"CC Patterson","year":"2019","journal-title":"Diabetologia"},{"key":"pmed.1003461.ref003","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2337\/dc15-0078","article-title":"Current state of Type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange Clinic Registry","volume":"38","author":"KM Miller","year":"2015","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"R Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"pmed.1003461.ref005","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2337\/dci19-0008","article-title":"SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution","volume":"42","author":"JI Wolfsdorf","year":"2019","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref006","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"JB Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref007","doi-asserted-by":"crossref","first-page":"l1328","DOI":"10.1136\/bmj.l1328","article-title":"Efficacy and safety of dual SGLT 1\/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials","volume":"365","author":"G Musso","year":"2019","journal-title":"BMJ"},{"key":"pmed.1003461.ref008","doi-asserted-by":"crossref","first-page":"m4147","DOI":"10.1136\/bmj.m4147","article-title":"Diabetic ketoacidosis with SGLT2 inhibitors","volume":"371","author":"G Musso","year":"2020","journal-title":"BMJ"},{"key":"pmed.1003461.ref009","unstructured":"Astellas Pharma. Approval of Suglat tablets, selective SGLT2 inhibitor, for additional indication of type 1 diabetes mellitus and additional dosage and administration in Japan. Press Release. https:\/\/www.astellas.com\/system\/files\/news\/2018-12\/181221_2_Eg_2.pdf. Accessed December 24., 2018."},{"key":"pmed.1003461.ref010","unstructured":"AstraZeneca. 2019\/forxiga-approved-in-japan-for-type-1-diabetes-27032019. html. 2019. Accessed March 27, 2019. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/"},{"key":"pmed.1003461.ref011","unstructured":"https:\/\/www.ema.europa.eu\/en\/news\/new-add-treatment-insulin-treatment-certain-patients-type-1-diabetesAstraZeneca. Forxiga approved in Europe for type-1 diabetes [media release]."},{"key":"pmed.1003461.ref012","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S2213-8587(19)30265-7","article-title":"NICE guidance on dapagliflozin with insulin for type 1 diabetes","volume":"7","author":"AI Adler","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"pmed.1003461.ref013","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S2213-8587(20)30066-8","article-title":"NICE guidance on sotagliflozin for type 1 diabetes","volume":"8","author":"AI Adler","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"pmed.1003461.ref014","unstructured":"https:\/\/www.globenewswire.com\/news-release\/2019\/03\/22\/1759502\/0\/en\/Sanofi-FDA-issues-Complete-Response-Letter-for-Zynquista-TM-sotagliflozin.html"},{"key":"pmed.1003461.ref015","unstructured":"https:\/\/www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2019\/update-on-us-regulatory-decision-for-farxiga-in-type-1-diabetes-15072019.html"},{"key":"pmed.1003461.ref016","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association Of Clinical Endocrinologists And American College Of Endocrinology Position Statement On The Association Of SGLT-2 Inhibitors And Diabetic Ketoacidosis","volume":"22","author":"Y Handelsman","year":"2016","journal-title":"Endocr Pract"},{"key":"pmed.1003461.ref017","doi-asserted-by":"crossref","first-page":"117","DOI":"10.15277\/bjd.2018.184","article-title":"Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose contransporter-2(SGLT-2) inhibitors in type 1 diabetes","volume":"18","author":"U Dashora","year":"2018","journal-title":"Br J Diabetes"},{"key":"pmed.1003461.ref018","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors","volume":"42","author":"T Danne","year":"2019","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref019","unstructured":"https:\/\/search.usa.gov\/search?utf8=%E2%9C%93&affiliate=fda&query=sotagliflozin&commit=Search"},{"key":"pmed.1003461.ref020","unstructured":"https:\/\/www.ema.europa.eu\/en\/search\/search?search_api_views_fulltext=sotagliflozin"},{"key":"pmed.1003461.ref021","unstructured":"https:\/\/ss.pmda.go.jp\/en_all\/search.x?q=sotagliflozin&ie=UTF-8&page=1&x=30&y=11"},{"key":"pmed.1003461.ref022","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc09-9032","article-title":"Hyperglycemic crises in adult patients with diabetes","volume":"32","author":"AE Kitabchi","year":"2009","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref023","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2337\/dc17-1600","article-title":"International Consensus on Use of Continuous Glucose Monitoring","volume":"40","author":"T Danne","year":"2017","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref024","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/dia.2013.0205","article-title":"Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control","volume":"16","author":"J Soupal","year":"2014","journal-title":"Diabetes Technol Ther"},{"key":"pmed.1003461.ref025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1530\/EJE-14-0911","article-title":"Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis","volume":"173","author":"E Donga","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"pmed.1003461.ref026","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.2337\/dc17-1624","article-title":"Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange","volume":"40","author":"G Agiostratidou","year":"2017","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref027","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4158\/EP14145.PS","article-title":"Consensus statement by the American Association of Clinical Endocrinologists\/American College of Endocrinology insulin pump management task force","volume":"20","author":"G Grunberger","year":"2014","journal-title":"Endocr Pract"},{"key":"pmed.1003461.ref028","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1177\/193229681000400516","article-title":"Guidelines for Insulin Dosing in Continuous Subcutaneous Insulin Infusion Using New Formulas from a Retrospective Study of Individuals with Optimal Glucose Levels","volume":"4","author":"J Walsh","year":"2010","journal-title":"J Diabetes Sci Technol"},{"key":"pmed.1003461.ref029","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","article-title":"Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales","volume":"110","author":"Global Diabetic Retinopathy Project Group","year":"2003","journal-title":"Ophthalmology"},{"key":"pmed.1003461.ref030","unstructured":"https:\/\/www.meddra.org\/ Last accessed on July 21st, 2019"},{"key":"pmed.1003461.ref031","unstructured":"Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.2.0. The Cochrane Collaboration; updated March 2011. Accessed at www.cochrane-handbook.org on 14 July 2019."},{"key":"pmed.1003461.ref032","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jclinepi.2017.12.004","article-title":"Recommendations for assessing the risk of bias in systematic reviews of health-care interventions","volume":"97","author":"M Viswanathan","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"pmed.1003461.ref033","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1740774515602688","article-title":"Fallacies of last observation carried forward analyses","volume":"13","author":"JM Lachin","year":"2016","journal-title":"Clin Trials"},{"key":"pmed.1003461.ref034","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3233\/JRS-2012-0574","article-title":"Sponsorship bias in clinical research","volume":"24","author":"J Lexchin","year":"2012","journal-title":"Int J Risk Saf Med"},{"key":"pmed.1003461.ref035","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005053-200209000-00002","article-title":"Design and reporting modifications in industry sponsored comparative psychopharmacology trials","volume":"190","author":"DJ Safer","year":"2002","journal-title":"J Nerv Ment Dis"},{"key":"pmed.1003461.ref036","unstructured":"National Research Council. Panel on Handling Missing Data in Clinical Trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education. Washington, DC: The National Academies Press; 2010. The prevention and treatment of missing data in clinical trials."},{"key":"pmed.1003461.ref037","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1001\/jama.299.15.1813","article-title":"Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation","volume":"299","author":"BM Psaty","year":"2008","journal-title":"JAMA"},{"key":"pmed.1003461.ref038","first-page":"557","article-title":"Medical specialists and pharmaceutical industry-sponsored research: A survey of the Australian experience","volume":"182","author":"DA Henry","year":"2005","journal-title":"MJA"},{"key":"pmed.1003461.ref039","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.295.14.1645","article-title":"Constraints on publication rights in ndustry-initiated clinical trials","volume":"295","author":"PC G\u00f8tzsche","year":"2006","journal-title":"JAMA"},{"key":"pmed.1003461.ref040","unstructured":"Review Manager (RevMan) [computer program]. Version 5.3. Copenhagen, Denmark: Nordic Cochrane Center, Cochrane Collaboration; 2012."},{"key":"pmed.1003461.ref041","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration","volume":"339","author":"A Liberati","year":"2009","journal-title":"BMJ"},{"key":"pmed.1003461.ref042","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"RM Turner","year":"2012","journal-title":"Int J Epidemiol"},{"key":"pmed.1003461.ref043","doi-asserted-by":"crossref","first-page":"j573","DOI":"10.1136\/bmj.j573","article-title":"Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?","volume":"356","author":"DJ Fisher","year":"2017","journal-title":"BMJ"},{"key":"pmed.1003461.ref044","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"G Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"pmed.1003461.ref045","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"SG Thompson","year":"2002","journal-title":"Stat Med"},{"key":"pmed.1003461.ref046","volume-title":"Chapter 20. Meta-Regression","author":"M Borenstein","year":"2009"},{"key":"pmed.1003461.ref047","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/dom.12882","article-title":"Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting \u03b2-hydroxybutyrate levels in a phase IIa pilot study","volume":"19","author":"RR Henry","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"pmed.1003461.ref048","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/sim.1752","article-title":"Controlling the risk of spurious findings from meta-regression","volume":"23","author":"JP Higgins","year":"2004","journal-title":"Stat Med"},{"key":"pmed.1003461.ref049","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"MJ Bradburn","year":"2007","journal-title":"Stat Med"},{"key":"pmed.1003461.ref050","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/0895-4356(96)00025-X","article-title":"Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis","volume":"49","author":"GW Sun","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"pmed.1003461.ref051","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jclinepi.2014.12.014","article-title":"The number of subjects per variable required in linear regression analyses","volume":"68","author":"PC Austin","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"pmed.1003461.ref052","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc13-2955","article-title":"Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study","volume":"38","author":"RR Henry","year":"2015","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref053","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/dom.13593","article-title":"Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes","volume":"21","author":"H Watada","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"pmed.1003461.ref054","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1210\/jc.2016-1451","article-title":"Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes","volume":"101","author":"ND Kuhadiya","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"pmed.1003461.ref055","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"DEPICT-1 Investigators","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"pmed.1003461.ref056","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study","volume":"41","author":"DEPICT-1 Investigators","year":"2018","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref057","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial","volume":"41","author":"C Mathieu","year":"2018","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref058","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/dom.13679","article-title":"Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial","volume":"21","author":"K Kaku","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"pmed.1003461.ref059","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1111\/dom.13807","article-title":"Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial","volume":"21","author":"K Kaku","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"pmed.1003461.ref060","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes","volume":"38","author":"RR Henry","year":"2015","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref061","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2337\/dc15-1995","article-title":"Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes","volume":"39","author":"AL Peters","year":"2016","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref062","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2337\/dc16-1353","article-title":"The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes","volume":"40","author":"HW Rodbard","year":"2017","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref063","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/dom.12494","article-title":"Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)","volume":"17","author":"TR Pieber","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"pmed.1003461.ref064","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/dia.2016.0261","article-title":"Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1)","volume":"19","author":"S Famulla","year":"2017","journal-title":"Diabetes Technol Ther"},{"key":"pmed.1003461.ref065","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials","volume":"41","author":"J Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref066","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/dom.13351","article-title":"Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial","volume":"20","author":"A Shimada","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"pmed.1003461.ref067","first-page":"S409","article-title":"A 12-week dose-ranging study of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem4)","volume":"60","author":"C Baker","year":"2017","journal-title":"Diabetologia"},{"key":"pmed.1003461.ref068","unstructured":"https:\/\/www.easd.org\/virtualmeeting\/home.html#!resources\/a-12-week-dose-ranging-study-of sotagliflozin-a-dual-sglt1-and-sglt2-inhibitor-as-adjunct-therapy-to-insulin-in-type-1-diabetes intandem4Dose-ranging Study in Patients With Type 1 Diabetes Mellitus (inTandem4)"},{"key":"pmed.1003461.ref069","first-page":"S87","article-title":"The Sotagliflozin JDRF Study Writing Group. Efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct to insulin in young adults with poorly controlled type 1 diabetes (JDRF Study)","volume":"60","author":"B Bode","year":"2017","journal-title":"Diabetologia"},{"key":"pmed.1003461.ref070","unstructured":"https:\/\/www.easd.org\/virtualmeeting\/home.html#!resources\/efficacy-and-safety-of-sotagliflozin-a-dual-sglt1-and-sglt2-inhibitor-as-adjunct-to-insulin-in-young-adults-with-poorly-controlled-type-1-diabetes-jdrf-study-15ae18d4-b8f6-439c-87ea-2f19dcad388e"},{"key":"pmed.1003461.ref071","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2337\/dc14-2806","article-title":"Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes","volume":"38","author":"AT Sands","year":"2015","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref072","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study","volume":"41","author":"JB Buse","year":"2018","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref073","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study","volume":"41","author":"T Danne","year":"2018","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref074","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes","volume":"377","author":"SK Garg","year":"2017","journal-title":"N Engl J Med"},{"key":"pmed.1003461.ref075","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors","volume":"38","author":"J Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"pmed.1003461.ref076","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41467-019-08466-w","article-title":"Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats","volume":"10","author":"RJ Perry","year":"2019","journal-title":"Nat Commun"},{"key":"pmed.1003461.ref077","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function","volume":"138","author":"BL Neuen","year":"2018","journal-title":"Circulation"},{"key":"pmed.1003461.ref078","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"HJ Heerspink","year":"2016","journal-title":"Circulation"},{"key":"pmed.1003461.ref079","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1210\/jc.2013-1589","article-title":"Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry","volume":"98","author":"RS Weinstock","year":"2013","journal-title":"J Clin Endocrinol Metab"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T13:25:15Z","timestamp":1609248315000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003461"}},"subtitle":[],"editor":[{"given":"Weiping","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,29]]},"references-count":79,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003461","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,29]]}}}